Iambic and Takeda Pharmaceutical have entered into a multi-year partnership valued at over $1.7 billion to use artificial intelligence to design small-molecule drugs for cancer and gastrointestinal diseases. The agreement includes upfront payments, milestone payments, and royalties, showcasing a significant investment in AI-driven drug development.
Iambic , a privately held company, announced on Monday a multi-year partnership with Japan's Takeda Pharmaceutical, valued at over $1.7 billion. The collaboration will leverage artificial intelligence to design small-molecule drugs, specifically targeting cancer and gastrointestinal diseases. The financial arrangement includes upfront payments for Iambic and the potential to earn more than $1.7 billion based on development and commercial milestones, in addition to royalties on sales.
This deal represents Takeda's ongoing efforts to integrate artificial intelligence across its research and development operations. This strategic move follows a prior agreement with Nabla Bio last year, which concentrated on protein-based drugs. The pharmaceutical industry is increasingly embracing AI to accelerate drug discovery processes and reduce associated expenses. Experts forecast that the integration of AI could potentially halve drug development timelines in the coming years, signifying a transformative shift in the industry's approach to research and development.\Under the terms of the agreement, Takeda will gain access to NeuralPLexer, Iambic's advanced model that predicts how drug molecules interact and bind to proteins. Tom Miller, the Chief Executive of Iambic, highlighted the crucial role of understanding protein structure in effective drug development. He elaborated on the significance of knowing the target's shape, likening the process to sculpting in darkness without the necessary visual information. Iambic's approach combines AI-driven predictions with automated laboratories, aiming to compress drug development timelines to under two years. The efficiency of AI, when combined with automated lab processes, offers considerable promise for rapid drug discovery. Christopher Arendt, Takeda's Chief Scientific Officer, stated that the technology has the potential to substantially reduce research timelines. However, he emphasized that speed alone is not the sole benefit, pointing out that molecular quality is equally important for producing successful drug candidates. Miller also mentioned that AI tools can potentially eliminate months of traditional laboratory work, emphasizing the capability of AI to create drugs that would not have been possible using conventional methods. This highlights the innovative potential of AI in pharmaceutical research, opening up new possibilities in drug design and development. The deal underscores a growing trend of pharmaceutical companies investing in AI to enhance their research capabilities and accelerate the delivery of new therapies to patients. This collaborative effort could significantly contribute to advancing treatment options for both cancer and gastrointestinal diseases.\The partnership between Iambic and Takeda reflects a broader industry trend where drug developers are increasingly using AI to accelerate the drug discovery process and cut down costs. This signifies a shift in how pharmaceutical research is being conducted, leading to potentially faster timelines and more effective drug development. The use of AI in drug design is not just about speed, it also enables a deeper understanding of molecular interactions, leading to more refined and potentially more effective drugs. The AI technology can simulate and predict how drug molecules will bind to proteins, enabling scientists to design more effective drugs, which will potentially reduce the time and cost involved in traditional lab work. This is a game changer in the pharmaceutical industry and will reshape how the industry operates in the coming years. By leveraging AI, Iambic and Takeda are aiming to not only speed up drug development, but also create novel therapies that were previously impossible to create. This partnership is a testament to the transformative potential of artificial intelligence and its impact on the pharmaceutical industry
Artificial Intelligence Drug Discovery Pharmaceuticals Takeda Iambic
Malaysia Latest News, Malaysia Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
India and US Announce Interim Trade Deal, Modi Hails AgreementIndia and the US have agreed to an interim trade agreement aimed at boosting economic ties and global growth. The deal involves reduced US duties on Indian products and commitments for Indian purchases of US energy and industrial goods. The agreement comes amid tensions over India's oil purchases from Russia, with the US seeking to end the funding of the ongoing conflict in Ukraine.
Read more »
IOC Set to Announce New Transgender Athlete Eligibility PolicyThe International Olympic Committee (IOC) is poised to unveil a new policy regarding the eligibility of transgender athletes, expected within the first half of this year. This unified policy, resulting from a consensus among global sports leaders, aims to provide a consistent framework for major sporting events, including the Olympics. The policy emphasizes the protection of the female category and follows extensive consultation and a 'pause and reflect' period led by IOC President Kirsty Coventry.
Read more »
M’sia, India ties enter next levelMILAN, Feb 7 (Reuters) - Competing against gold medal favourite Ilia Malinin always motivates Yuma Kagiyama and pushes him to do better, the Japanese figure skater said after upstaging the American in the men's short programme in the team event at the Milano Cortina Olympics.
Read more »
Man Arrested After High-Speed Police Chase and Drug Seizure in KuantanA local man was arrested in Kuantan after a high-speed chase that resulted in a multi-vehicle accident. Police seized drugs estimated to be worth RM2,300. The suspect tested positive for drugs and faces charges related to drug offenses and the road accident.
Read more »
Child Opens Car Door, Triggers Multi-Vehicle Collision on Jalan Tun RazakA multi-vehicle accident on Jalan Tun Razak was caused by a child opening a car door, resulting in injuries and ongoing investigations. The incident involved six vehicles, including two motorcycles, and underscores the importance of road safety and child safety precautions.
Read more »
Singapore To Raise Vehicle Entry Permit Fees For Foreign Cars To RM155 Per Day On WeekdaysThe city-state will also scrap the annual 10 free VEP days and free weekday VEP hours, which currently allow foreign vehicles to enter the island without charge during certain periods.
Read more »